The Complete® SE SFA Study for the Treatment of SFA/PPA Lesions

NCT ID: NCT00814970

Last Updated: 2016-04-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 196 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-11-30
• Study Completion Date: 2013-12-31

Brief Summary

To evaluate the safety and efficacy of the Complete SE SFA Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) in subjects with symptomatic Peripheral Artery Disease (PAD).

Detailed Description

The Complete Self-Expanding (SE) SFA Stent is designed to be a permanent implant. It is cut from a nickel titanium alloy (Nitinol) tube and consists of a series of segments each connected to the next in a unique pattern to allow for flexibility and vessel conformability. Each segment consists of two struts and a crown (Figure 1). It is designed to produce optimal luminal diameter and increased scaffolding, and to maintain luminal patency.

Conditions

Peripheral Vascular Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Complete SE Vascular Stent System

COMPLETE SE Vascular Stent System - implantation of study device in native SFA and/or PPA for subjects with symptomatic ischemic peripheral arterial disease in the superficial femoral artery or proximal popliteal arteries with an occlusion or lesion greater or equal to 50 percent with lesions located above the knee and amenable to percutaneous treatment with angioplasty and vascular stent implantation.

Group Type: EXPERIMENTAL

Complete SE Vascular Stent System

Intervention Type: DEVICE

Complete SE Vascular Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or the Proximal Popliteal Artery (PPA) in subjects with symptomatic Peripheral Artery Disease (PAD).

Interventions

Complete SE Vascular Stent System

Complete SE Vascular Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or the Proximal Popliteal Artery (PPA) in subjects with symptomatic Peripheral Artery Disease (PAD).

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Rutherford 2-4, with an occlusion or de novo and/or restenotic SFA/PPA lesion ≥50% and ankle-brachial index/toe-brachial index (ABI/TBI) <0.90/0.80.

2. Target lesion located at least 1 cm distal to the take-off of the profunda femoris artery and at least 3 cm proximal to the highest point of the cortical margin of the femur;

3. Target vessel reference diameter is ≥4.0 mm and ≤7.0 mm (visual estimate);

4. Target lesion length is ≥4.0 cm and ≤14.0 cm (visual estimate);

5. Adequate distal run-off to the ankle in the target limb (defined as having at least one patent calf vessel <50% stenosed;

6. Life expectancy >12 months.

Exclusion Criteria

7. Women who do not have a negative serum or urine pregnancy test documented within 7 days prior to enrollment;

8. Any condition that precludes safe access with percutaneous transluminal angioplasty (PTA) devices, such as: excessive peripheral artery disease, unresolved fresh thrombus in the target lesion/vessel, or a target lesion/vessel that is excessively tortuous or calcified;

9. Lesions in contralateral SFA/PPA that require intervention during the index procedure, or within 30 days before or after the index procedure;

10. Previous treatment to the target lesion within the 3 months prior to enrollment; previous femoropopliteal bypass in target vessel; previous stenting of the target lesion;

11. Target lesion located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion;

12. Target lesion requires treatment other than standard PTA prior to stent placement (i.e., no other devices or procedures such as cutting balloons and laser atherectomy are permitted to be used during the index procedure);

13. History of bleeding diatheses or coagulopathy or will refuse blood transfusions;

14. Known impaired renal function, defined as creatinine >2.5 mg/dl;

15. Known platelet count <80,000 cells/mm3 or >700,000 cells/mm3;

16. Known white blood cell (WBC) of <3,000 cells/mm3;

17. Participation in another investigational device or drug study and has not completed the primary endpoint(s) or which clinically interferes with the Complete SE SFA Study endpoints, or previously enrolled in the Complete SE SFA Study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medtronic Endovascular

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

John Laird, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, Davis

Dierk Scheinert, PD

Role: PRINCIPAL_INVESTIGATOR

Park-Krankenhaus Leipzig-Sudost GmbH

Locations

Washington Hospital

Fremont, California, United States

N. Florida Regional Medical Center

Gainesville, Florida, United States

Munroe Regional Medical Center

Ocala, Florida, United States

AnMed Health

Anderson, South Carolina, United States

Countries

United States

References

Laird JR, Jain A, Zeller T, Feldman R, Scheinert D, Popma JJ, Armstrong EJ, Jaff MR; Complete SE Investigators. Nitinol stent implantation in the superficial femoral artery and proximal popliteal artery: twelve-month results from the complete SE multicenter trial. J Endovasc Ther. 2014 Apr;21(2):202-12. doi: 10.1583/13-4548R.1.

Reference Type: DERIVED

PMID: 24754279 (View on PubMed)

Other Identifiers

IDE G080143

Identifier Type: OTHER

Identifier Source: secondary_id

IP105

Identifier Type: -

Identifier Source: org_study_id